IFRX logo

IFRX
InflaRx N.V.

10,451
Mkt Cap
$61.45M
Volume
183,575.00
52W High
$1.94
52W Low
$0.7113
PE Ratio
-0.87
IFRX Fundamentals
Price
$0.923
Prev Close
$0.9154
Open
$0.9143
50D MA
$0.9703
Beta
1.06
Avg. Volume
288,171.41
EPS (Annual)
-$0.8457
P/B
1.16
Rev/Employee
$2,423.41
$91.65
Loading...
Loading...
News
all
press releases
InflaRx Showcases Izicopan HS and CSU Data, Streamlines C5aR Strategy at Oppenheimer Conference
InflaRx (NASDAQ:IFRX) highlighted recent clinical updates and strategic priorities for its complement inhibition platform during a presentation at Oppenheimer's 36th Annual Healthcare Life Sciences...
MarketBeat·7d ago
News Placeholder
More News
News Placeholder
InflaRx Spotlights Izicopan HS Data, Phase 2b Plans and 30% Cost Cuts at Guggenheim Summit
InflaRx (NASDAQ:IFRX) highlighted progress on its oral C5a receptor 1 (C5aR) antagonist izicopan and outlined upcoming development plans during a presentation at the Guggenheim Outlook Biotech Summit...
MarketBeat·20d ago
News Placeholder
InflaRx N.V. (NASDAQ:IFRX) Given Consensus Recommendation of "Moderate Buy" by Analysts
InflaRx N.V. (NASDAQ:IFRX - Get Free Report) has received a consensus rating of "Moderate Buy" from the seven brokerages that are presently covering the company, MarketBeat.com reports. One research...
MarketBeat·28d ago
News Placeholder
InflaRx N.V. (NASDAQ:IFRX) Receives Consensus Rating of "Moderate Buy" from Analysts
Shares of InflaRx N.V. (NASDAQ:IFRX - Get Free Report) have received a consensus rating of "Moderate Buy" from the eight brokerages that are currently covering the stock, MarketBeat reports. One...
MarketBeat·2mo ago
News Placeholder
InflaRx Reopens Case For Axed Phase 3 Drug For Rare Skin Disorder
InflaRx presented data analyses from a terminated Phase 3 study on the potential treatment for rare skin condition.read more...
Benzinga·2mo ago
News Placeholder
Short Interest in InflaRx N.V. (NASDAQ:IFRX) Increases By 26.7%
InflaRx N.V. (NASDAQ:IFRX - Get Free Report) was the recipient of a significant growth in short interest in the month of December. As of December 15th, there was short interest totaling 2,745,086...
MarketBeat·2mo ago
News Placeholder
InflaRx (NASDAQ:IFRX) Receives Buy Rating from HC Wainwright
HC Wainwright restated a "buy" rating and set a $6.00 price target on shares of InflaRx in a research report on Tuesday...
MarketBeat·2mo ago
News Placeholder
InflaRx N.V. (NASDAQ:IFRX) Receives Consensus Rating of "Moderate Buy" from Analysts
InflaRx N.V. (NASDAQ:IFRX - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the eight brokerages that are presently covering the firm, MarketBeat Ratings reports...
MarketBeat·3mo ago
News Placeholder
InflaRx N.V. (NASDAQ:IFRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Shares of InflaRx N.V. (NASDAQ:IFRX - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the six ratings firms that are covering the stock, Marketbeat.com reports. One...
MarketBeat·3mo ago
News Placeholder
Is InflaRx NV Gaining or Losing Market Support?
read more...
Benzinga·4mo ago
<
1
2
...
>

Latest IFRX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.